MedDataX Logo

Study of the Clinical Efficacy of Autologous SCT in Patients With Critical Limb Ischemia

NCT ID: NCT01311011

Last Updated: 2011-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase II Prospective Study of the Clinical Efficacy of Autologous SCT in patients with Critical Limb Ischemia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase II Prospective Study of the Clinical Efficacy of Autologous SCT in patients with Critical Limb Ischemia

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Limb Ischemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Critical Limb Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SCT

SCT

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with Critical Limb Ischemia

Exclusion Criteria

* Patients with other than Critical Limb Ischemia
Minimum Eligible Age

14 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

King Faisal Specialist Hospital & Research Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

H Al-Zahrani, M.D.

Role: PRINCIPAL_INVESTIGATOR

KFSH & RC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kfsh & Rc

Riyadh, , Saudi Arabia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Saudi Arabia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

H Al-Zahrani, M.D.

Role: CONTACT

Phone: +966-1-4423949

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RAC# 2081-026

Identifier Type: -

Identifier Source: secondary_id

RAC# 2081-026

Identifier Type: -

Identifier Source: org_study_id